Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natalie Mills

Physician Assistant Albuquerque, NM Physician Assistant

NPI 1568912327 CMS profile 10775960

5120 Masthead St Ne, Albuquerque, NM 87109

Open in the dashboard

General payments

$2,221

79 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Mills of Albuquerque, NM is reported in the CMS Open Payments database as having received $2,221 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $617 20
2024 General $481 19
2023 General $554 17
2022 General $367 12
2021 General $203 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Mills
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Natalie Mills were reported at $617. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Natalie Mills Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $203 $132 $37–$438 $132
2022 $367 $155 $48–$522 $149
2023 $554 $167 $52–$557 $160
2024 $481 $178 $55–$600 $164
2025 $617 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $546 18 payments
  2. AbbVie, Inc. $538 20 payments
  3. Genzyme Corporation $346 13 payments
  4. Janssen Biotech, Inc. $328 9 payments
  5. Incyte Corporation $174 4 payments
  6. Galderma Laboratories, L.P. $72 4 payments
  7. UCB, Inc. $37 2 payments
  8. Sun Pharmaceutical Industries Inc. $35 2 payments
  9. Lilly USA, LLC $34 2 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $31 1 payment
  11. Other $81 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,042 76 payments
  2. Education $179 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $489 14 payments
  2. RINVOQ $329 8 payments
  3. TREMFYA $328 9 payments
  4. OPZELURA $174 4 payments
  5. SKYRIZI $165 10 payments
  6. COSENTYX $158 6 payments
  7. Rhapsido $108 3 payments
  8. AKLIEF $47 3 payments
  9. BLU-U $35 2 payments
  10. Odomzo $35 2 payments
  11. Other $225 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

532

Median for Physician Assistant: 241

Drug cost

$204,984

Median for Physician Assistant: $4,110

Branded share of claims

7.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 18 $130,048
Dupixent Pen Dupilumab Brand 11 $60,789
Calcipotriene Generic 33 $3,049
Fluorouracil Generic 50 $2,566
Metronidazole Generic 39 $1,812
Clobetasol Propionate Generic 61 $1,407
Ketoconazole Generic 74 $1,166
Tacrolimus Generic 16 $1,100
Betamethasone Dipropionate Generic 22 $826
Doxycycline Hyclate Generic 25 $690

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$150,202

Of which drugs: $22,406

Medicare patients

592

Average age 74

Services billed

4,033

293 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 44%
Ischemic heart disease 17%
Diabetes 16%
Osteoporosis 16%
Cancer 15%
Chronic kidney disease 13%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 21 72 $22,397

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $95
$95 — —
SKYRIZI
  • AbbVie, Inc. $60
$60 — —
RINVOQ
  • AbbVie, Inc. $40
$40 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $28
$28 — —
DUPIXENT
  • GENZYME CORPORATION $21
$21 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record